ADAPAdaptimmune Therapeutics plc

ADAP Stock Price, Valuation & Chart | Adaptimmune Therapeutics plc

Compare

$0.050+0.00 (-3.00%)

At close · 21 Nov 2025, 02:30 pm

Sector: Healthcare Industry: Biotechnology ADAP intrinsic value ADAP calculated fair value vs price

Overview Financials Dividends Ratios

ADAP Historical price chart

ADAP Key Stats

Fair Value

Disclaimer

Disclaimer: This fair value estimate is for informational purposes only and should not be considered as investment advice. Fair value calculations are based on DCF (Discounted Cash Flow), P/E Multiple, and P/S Multiple models and assumptions that may not reflect actual market conditions. Always conduct your own research and consult with a financial advisor before making investment decisions.

Unlock

Market Capitalization75.16M

PE Ratio-0.07

EPS-0.66

Trading Volume1.68M

Today's High/Low0.06/0.04

Dividend Yield0.00

52 Week High/Low0.86/0.02

Shares Outstanding1.55B

ADAP Financial Statement

ADAP Analyst ratings

ADAP Analysis & performance metrics

ADAP Company profile

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United…

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4 that is in phase II clinical trials with…

ADAP Management team

Name

Position

William C. A. Bertrand Jr., Esq., J.D.COO

Chief Operating Officer & Chief Compliance Officer

Helen Katrina Tayton-Martin MBA, Ph.D.

Co-Founder

John Lunger

Chief Patient Supply Officer

Juli P. Miller Ph.D.

Vice President of Corporate Affairs & Investor Relations

Elliot Norry B.A., M.D.

Chief Medical Officer

Joanna Brewer Ph.D.

Chief Scientific Officer

Dana LynchCTO

Senior Director of Corporate Communications

Adrian G. RawcliffeCEO

Chief Executive Officer & Director

Name

Position

William C. A. Bertrand Jr., Esq., J.D.COO

Chief Operating Officer & Chief Compliance Officer

Helen Katrina Tayton-Martin MBA, Ph.D.

Co-Founder

John Lunger

Chief Patient Supply Officer

Juli P. Miller Ph.D.

Vice President of Corporate Affairs & Investor Relations

Elliot Norry B.A., M.D.

Chief Medical Officer

Joanna Brewer Ph.D.

Chief Scientific Officer

Dana LynchCTO

Senior Director of Corporate Communications

Adrian G. RawcliffeCEO

Chief Executive Officer & Director

Management Team

William C. A. Bertrand Jr., Esq., J.D.COO

Chief Operating Officer & Chief Compliance Officer

Helen Katrina Tayton-Martin MBA, Ph.D.

Co-Founder

John Lunger

Chief Patient Supply Officer

Juli P. Miller Ph.D.

Vice President of Corporate Affairs & Investor Relations

Elliot Norry B.A., M.D.

Chief Medical Officer

Joanna Brewer Ph.D.

Chief Scientific Officer

Dana LynchCTO

Senior Director of Corporate Communications

Adrian G. RawcliffeCEO

Chief Executive Officer & Director

Management

William C. A. Bertrand Jr., Esq., J.D.COO

Chief Operating Officer & Chief Compliance Officer

Helen Katrina Tayton-Martin MBA, Ph.D.

Co-Founder

John Lunger

Chief Patient Supply Officer

Juli P. Miller Ph.D.

Vice President of Corporate Affairs & Investor Relations

Elliot Norry B.A., M.D.

Chief Medical Officer

Joanna Brewer Ph.D.

Chief Scientific Officer

Dana LynchCTO

Senior Director of Corporate Communications

Adrian G. RawcliffeCEO

Chief Executive Officer & Director

Total 8 executives

ADAP Frequently asked questions

What is Adaptimmune Therapeutics plc (ADAP) Stock Price?

Current stock price of Adaptimmune Therapeutics plc (ADAP) stock is $0.050. The stock price is -3.00% lower in the session. The intraday range can be seen from this page. Volume of Adaptimmune Therapeutics plc (ADAP) stock is 1.68M.

Last updated at 21 Nov 2025, 02:30 pm.

Why is the Adaptimmune Therapeutics plc (ADAP) stock price going up or down today?

The stock price of Adaptimmune Therapeutics plc (ADAP) can change with earnings, company news, and overall market sentiment. Adaptimmune Therapeutics plc operates in the Healthcare / Biotechnology market, so sector-wide moves can also affect the share price. Use the live price, percentage change, and volume on this page to judge whether a move looks meaningful.

Is the Adaptimmune Therapeutics plc stock expensive at its current price?

Whether Adaptimmune Therapeutics plc looks expensive depends on valuation metrics versus its growth outlook. The P/E ratio shown for ADAP on this page is -0.07. EPS on this page is -0.66. Compare those figures with peers and growth expectations before deciding if the current Adaptimmune Therapeutics plc price is justified.

How has the stock price of Adaptimmune Therapeutics plc (ADAP) performed historically?

Historical performance for Adaptimmune Therapeutics plc (ADAP) is shown on the price chart on this page. Review multi-period moves alongside volume to see how ADAP reacted to past earnings and market events.

Should I buy Adaptimmune Therapeutics plc (ADAP) stock, at this price?

Buying Adaptimmune Therapeutics plc (ADAP) depends on your risk tolerance, time horizon, and portfolio needs. As a Healthcare name, weigh the live quote, key stats, and valuation links on this page rather than a single price point.